Vérane Achard1,2, Paul Martin Putora3,4, Aurelius Omlin5, Thomas Zilli1,2, Stefanie Fischer5. 1. Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland. 2. Faculty of Medicine, Geneva University, Geneva, Switzerland. 3. Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 4. Faculty of Medicine, University of Bern, Bern, Switzerland. 5. Department of Medical Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Abstract
BACKGROUND: Metastatic prostate cancer (PCa) is associated with considerable diminished overall survival (OS). Standard treatment for metastatic PCa has long been androgen deprivation therapy alone, with patients initially responding to this treatment and then progressing to a castration-resistant phase. SUMMARY: The advent of novel therapeutic agents has changed this paradigm, with high-level evidence that upfront combination therapy with either docetaxel or new hormonal agents results in improved OS for patients with metastatic hormone-sensitive PCa. In the absence of a comprehensive clinical trial investigating the comparative efficacy and safety of all agents, clinicians are responsible for choosing the most appropriate therapy in close coordination with patients. Furthermore, the same therapeutic agents are also efficient in the castration-resistant phase, leading to the issue of the best therapeutic sequence. Finally, along with systemic therapy and molecular imaging advancements, radiotherapy was investigated in the oligometastatic setting, whether it is to treat the primary tumour or metastases. Key Messages: In this complex landscape, where providers have multiple effective therapeutic options to treat metastatic PCa patients, priority must be given to determine which treatment combination and sequence is best suited to a particular patient, given his comorbidities and preferences.
BACKGROUND: Metastatic prostate cancer (PCa) is associated with considerable diminished overall survival (OS). Standard treatment for metastatic PCa has long been androgen deprivation therapy alone, with patients initially responding to this treatment and then progressing to a castration-resistant phase. SUMMARY: The advent of novel therapeutic agents has changed this paradigm, with high-level evidence that upfront combination therapy with either docetaxel or new hormonal agents results in improved OS for patients with metastatic hormone-sensitive PCa. In the absence of a comprehensive clinical trial investigating the comparative efficacy and safety of all agents, clinicians are responsible for choosing the most appropriate therapy in close coordination with patients. Furthermore, the same therapeutic agents are also efficient in the castration-resistant phase, leading to the issue of the best therapeutic sequence. Finally, along with systemic therapy and molecular imaging advancements, radiotherapy was investigated in the oligometastatic setting, whether it is to treat the primary tumour or metastases. Key Messages: In this complex landscape, where providers have multiple effective therapeutic options to treat metastatic PCa patients, priority must be given to determine which treatment combination and sequence is best suited to a particular patient, given his comorbidities and preferences.
Authors: Vérane Achard; Kelly Ceyzériat; Benjamin B Tournier; Giovanni B Frisoni; Valentina Garibotto; Thomas Zilli Journal: Front Oncol Date: 2021-12-15 Impact factor: 6.244
Authors: Pengfei Xu; Logan J Wasielewski; Joy C Yang; Demin Cai; Christopher P Evans; William J Murphy; Chengfei Liu Journal: Biomedicines Date: 2022-07-22